Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Syngen Biotech Co.,Ltd. (8279.TWO)
Tainan City, TW
Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include microbial pharmaceutical raw materials, biological pesticides, fertilizers, biochemical nutritional products, and preventive medicines. The company further manufactures dietary supplements and provides comprehensive contract manufacturing services for supplements, accommodating various formats such as sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies. Syngen Biotech also develops and markets science-backed bioactive pharmaceutical ingredients (APIs) under proprietary brands including Oraltics, IMMUPHYLA, V3, ST4SanTex, GUARDSPO, benefiGANO, EXPUNERGY, and BIOJOVIAL. Additional services encompass private labelling, organic food OEM/ODM, explosion-proof extraction, brand agency, and wholesale distribution. Syngen Biotech caters to numerous industries, such as sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox. The company actively exports its products to approximately 20 countries worldwide.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.43% | +0.31% | -9.11% | -21.62% | -24.96% | -16.55% | -28.56% | -45.77% | -5.10% | +79.59% | +160.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+6.1% ★ Q1'26: -14.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+13.2% Q1'26: -45.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+9.4% Q1'26: +12.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+15.3% ★ Q1'26: +10.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+11.0% ★ Q1'26: +5.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.97× ★ Q1'26: 1.82× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
958.50M
est.
|
1.08B
est.
|
1.30B
est: 1.29B (+0.2%)
|
1.31B
est: 1.40B (-6.6%)
|
1.47B
est: 1.46B (+0.8%)
|
1.93B
est: 1.93B (0.0%)
|
1.84B
est: 1.84B (0.0%)
|
2.01B
est: 1.93B (+4.5%)
|
2.14B
est: 2.02B (+5.6%)
|
| EBITDA |
230.67M
est.
|
260.99M
est.
|
308.11M
est: 311.48M (-1.1%)
|
342.51M
est: 337.73M (+1.4%)
|
380.42M
est: 351.23M (+8.3%)
|
448.88M
est: 464.70M (-3.4%)
|
442.14M
est: 442.32M (0.0%)
|
423.57M
est: 422.07M (+0.4%)
|
326.98M
est: 443.31M (-26.2%)
|
| EBIT |
178.97M
est.
|
202.49M
est.
|
242.90M
est: 241.67M (+0.5%)
|
265.84M
est: 262.03M (+1.5%)
|
298.70M
est: 272.51M (+9.6%)
|
362.38M
est: 360.55M (+0.5%)
|
342.66M
est: 343.18M (-0.2%)
|
308.89M
est: 340.66M (-9.3%)
|
326.98M
est: 357.81M (-8.6%)
|
| Net Income |
173.18M
est.
|
155.67M
est.
|
188.77M
est: 197.90M (-4.6%)
|
215.55M
est: 216.75M (-0.6%)
|
237.77M
est: 238.18M (-0.2%)
|
321.24M
est: 334.22M (-3.9%)
|
274.83M
est: 271.82M (+1.1%)
|
240.21M
est: 307.10M (-21.8%)
|
271.59M
est: 324.45M (-16.3%)
|
| SGA |
145.52M
est.
|
164.65M
est.
|
172.09M
est: 196.51M (-12.4%)
|
194.51M
est: 213.07M (-8.7%)
|
197.02M
est: 221.59M (-11.1%)
|
262.63M
est: 293.17M (-10.4%)
|
302.88M
est: 279.05M (+8.5%)
|
354.38M
est: 235.40M (+50.5%)
|
—
est: 247.25M (-100.0%)
|
| EPS |
6.38
est.
|
5.74
est.
|
7.86
est: 7.30 (+7.7%)
|
7.95
est: 7.99 (-0.5%)
|
8.77
est: 8.78 (-0.1%)
|
11.85
est: 12.32 (-3.8%)
|
10.14
est: 10.02 (+1.2%)
|
8.86
est: 11.33 (-21.8%)
|
10.02
est: 11.97 (-16.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wei Ren Chen | Chairman of the Board and President | — | — |
| Zhi Ming Huang | Finance Manager | — | — |
| Zihui Wang | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8279.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
